Blackstone Inc’s Clovis Oncology, Inc. CLVS Stock Holding History

Blackstone Inc’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,278	Closed	-$307K	–	45
2017 Q2	$307K	Buy	+3,278	New	+$201K	﹤0.01%	37

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Blackstone Inc's CLVS Position: Q3 2017 in Review

Blackstone Inc sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 3,278 shares — an estimated $307K sold.

Blackstone Inc first reported a position in CLVS in Q2 2017 and held it in 1 quarter. The position peaked at $307K in Q2 2017. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

Blackstone Inc reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
Blackstone Inc sold 3,278 Clovis Oncology, Inc. shares in Q3 2017, an estimated $307K.
Blackstone Inc first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 1 quarter.
Blackstone Inc's Clovis Oncology, Inc. position peaked at $307K in Q2 2017.
255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Blackstone Inc's 13F filing for Q3 2017, filed 14 Nov 2017.